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  Abstract 
Consequence analysis of postulated accident releases requires that assumptions be made on the 
material form being released.  This paper documents the general methodology for the selection 
of the proper material form (i.e., chemical compound) and its associated solubility category that 
is being used at Savannah River Site (SRS).  The solubility characteristics of a radionuclide 
inhaled into the body directly influences the uptake and retention of that radionuclide, and 
consequently, the committed effective dose equivalent (CEDE).  The CEDE per unit uptake is 
reflected in the inhalation dose conversion factor (DCF) of a given radionuclide.  The 
methodology that is presented here provides a strategy that is used in SRS applications for 
specifying reasonably conservative inhalation DCFs based on consideration of chemical 
compound forms that are expected from SRS-based source terms arising from postulated 
accident conditions. 
Introduction 
The inhalation DCFs are key input data of the dosimetry calculations of MACCS21 and similar 
radiological consequence codes used for safety analysis applications.  Sometimes, bounding 
default DCFs are used without questioning the validity of these DCFs to the inventory 
challenged by the accident condition being analyzed.  The approach used at SRS recognizes that 
CEDEs are chemical compound-dependent and many radionuclides can have multiple inhalation 
DCF values depending on the chemical and physical nature of the radionuclide under 
consideration.  Specifically, the methodology for DCF selection makes use of the 
characterization of most SRS source terms as being similar in chemistry to the inventory 
challenged by the accident condition.  In general, this can be interpreted as material in oxide 
powder, oxide metal or nitrate solution forms. 
The methodology at the SRS for specifying inhalation DCFs has been applied over recent years 
to the DCF database set from Federal Guidance Report (FGR) 112 and more recently to the set 
that is based on Publications 68 (Worker)3 and 72 (General Public)4 of the International 
Commission on Radiological Protection (ICRP).  This paper will present the methodology in 
terms of the ICRP 68/72 DCFs, but the methodology presented here is easily adaptable to the 
FGR-11 based DCFs.  The ICRP 68/72 inhalation DCFs are based on ICRP 1990 
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recommendations on radiation protection standards in Publication 605 as well as the revised 
kinetic and dosimetric model of the respiratory tract in Publication 666.  Since the issuance of 
ICRP Publications 68 and 72, the ICRP has issued a compact disc with a DCF database,7 using 
the same models.  The database gives both individual organ and effective dose coefficients.  
Additionally, the database gives the user greater flexibility by including inhalation DCFs for ten 
particle sizes. 
Since plutonium in the source term is often the main contributor to dose, specifying the 
appropriate inhalation DCFs for plutonium radionuclides is especially important and thus given 
particular emphasis.  Recent guidance from ICRP publications on plutonium lung absorption has 
focused on the various oxide forms of plutonium and the importance of the material’s history, 
especially the method of oxide formation.  High-fired plutonium oxide results in insoluble 
material form with a slower lung absorption rate than plutonium oxide that results from air 
oxidation at ambient temperatures.8 
General Discussion 
Solubility and Bodily Absorption 
Chemical form of inhaled material determines solubility and subsequent transport behavior 
within the body.  Three broad solubility categories have been defined for use with ICRP 68/72 
inhalation DCFs and are expressed in terms of lung absorption types categorized as fast (F), 
moderate (M), and slow (S).  These lung absorption types relate to the rate of absorption from 
the respiratory tract to body fluids as defined below: 
• Lung Absorption Type F: Deposited materials that are readily absorbed into body fluids 
from the respiratory tract (Fast absorption). 
• Lung Absorption Type M: Deposited materials that have intermediate rates of absorption 
into body fluids from the respiratory tract (Moderate absorption). 
• Lung Absorption Type S: Deposited materials that are relatively insoluble in the respiratory 
tract (Slow absorption). 
Association of Chemical Compound Forms and Lung Absorption Type 
The assignment of lung absorption type assignments to the various chemical compound forms in 
which radionuclides can exist is given in Annexe F of ICRP Publication 683 (Table 3 of FGR 11 
serves a similar function for the FGR-11 system2).  Some of the common chemical compound 
forms explicitly addressed include oxides, hydroxides, nitrates, halides, carbides, sulphides, 
sulphates, and fluorides. 
There are no apparent universal rules that govern the assignment of a specific chemical 
compound form (e.g., oxides) to a solubility category, so each radionuclide must be treated 
individually.  For example in the ICRP-68/72 system, thorium oxide is assigned to lung 
absorption type S, while technetium oxide is assigned to lung absorption type M.3  Furthermore, 
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a single lung absorption type may cover all chemical compound forms for a particular 
radionuclide (e.g., americium), while other radionuclides have chemical compound forms that 
span two lung absorption types (e.g., plutonium) or three (e.g., uranium) as shown by the 
examples below.3 
• Americium compounds are all lung absorption type M. 
• Plutonium compounds can be lung absorption type S (insoluble oxide) or lung absorption 
type M (all other plutonium compounds). 
• Uranium compounds can be lung absorption type S (UO2 and U3O8), lung absorption type M 
(UO3, UF4, and UCl4), or lung absorption type F (UF6, UO2F2, and UO2[NO3]2). 
Particle Size Effects 
The particle size also affects material transport in the body and thus the inhalation DCF value.  
The ICRP Publication 68 gives inhalation DCFs that are based on both 1-µm and 5-µm activity 
median aerodynamic diameter (AMAD).3  The AMAD signifies that fifty percent of the activity 
in the aerosol is associated with particles of aerodynamic diameter greater than the AMAD.  The 
1-µm and 5-µm AMAD particle sizes addressed in ICRP Publication 68 are broadly consistent 
with the particle-size range generally considered in accident analysis.  Recommended airborne 
release fractions given in DOE-HDBK-3010-94 are based on 10-µm aerodynamic equivalent 
diameter (AED) and less.9 
The ICRP 68/72 models predict greater deposition of larger particles in the upper respiratory 
tract, where the rate of absorption to the blood is relatively high.10  As a result for highly soluble 
particles (i.e., lung absorption type F), the total predicted absorption to the blood tends to greater 
for the 5-µm particles in comparison with the 1-µm particles.10  As an example, consider cesium 
for which all compound forms are categorized under lung absorption type F.  The 5-µm AMAD 
inhalation DCF for 137Cs is approximately 40% higher than that corresponding to 1 µm (i.e., 
6.7E-09 Sv/Bq versus 4.8E-09 Sv/Bq).3 
In contrast for particles that dissolve more slowly (lung absorption types M and S), the models 
predict that “a substantial portion of the deposited particles is cleared to the gastrointestinal tract 
by mechanical transport before there is sufficient dissolution to allow absorption of the 
radionuclide into blood”.10  The net effect tends to be lower inhalation DCFs for 5-µm particles 
in comparison with the 1-µm particles.  Take for example 238Pu and consider lung absorption 
type M.  The 5-µm AMAD inhalation DCF is approximately 30% lower than that corresponding 
to 1 µm (i.e., 3.0E-05 Sv/Bq versus 4.3E-05 Sv/Bq).3  Similar results are observed with other 
plutonium isotopes and thorium, americium, curium, and californium radionuclides that are 
characterized as lung absorption type M or S and which tend to have relatively high inhalation 
DCFs. 
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Practical Applications 
Well Characterized Source Term Material 
For a well characterized source term, specifying the appropriate inhalation DCFs is relatively 
straightforward following the recommendations given in Annexe F of ICRP Publication 68 for 
relating chemical compound forms to a lung absorption type for each radionuclide.  For some 
radionuclides, a specific lung absorption type will be identified for the specific chemical form of 
interest, and the inhalation DCF associated with that lung absorption type is applicable.  For 
other radionuclides, Annexe F of ICRP Publication 68 will not explicitly associate the chemical 
form of interest to a lung absorption type.  In these cases, ICRP Publication 68 identifies a lung 
absorption type to be used for either unspecified compounds or all compounds that is 
appropriate.3 
The ICRP Publication 72 gives inhalation DCFs based on particles of 1-µm AMAD.4  For 
radiological exposures to members of the general public, ICRP Publication 71 recommends a 
particle size of 1-µm AMAD as a default value.8  The older set of inhalation DCFs that are 
documented in FGR 11 are also based on the 1-µm AMAD particle size.2 
The ICRP Publication 68 gives inhalation DCFs that are based on both 1-µm and 5-µm AMAD 
particle sizes.3  The ICRP Publication 68 recommends a particle size of 5-µm AMAD as a 
default value for occupational exposures stating that 5-µm AMAD is generally more 
representative of workplace aerosols.3  The inhalation DCFs based on 1-µm AMAD are also 
given since this smaller particle size has been shown from field measurements to be more 
appropriate “in some situations”.3  Thus, a well-characterized inventory of powder material will 
include information on particle size to guide the analyst in selection on the more appropriate set 
of inhalation DCFs to use for the worker consequence analysis.  Note that the 1-µm AMAD 
DCFs from ICRP Publications 68 and 72 do not always exactly agree with one another based on 
differences in the models used for the worker and general public, respectively.  The differences 
though are generally not that significant (e.g., 10% or less). 
Particles of 10-µm AED and less particles are generally assumed to be released in unmitigated 
accident analysis,9 for which either the 1-µm or 5-µm AMAD DCFs would be applicable.  In a 
mitigated accident scenario in which active ventilation systems are credited, filters not only 
reduce the magnitude of the source term but also reduce the characteristic particle size that is 
released to the atmosphere.  For these scenarios, inhalation DCFs that are based on a 
characteristic particle size much less than 1-µm (e.g., 0.1 µm) may be more appropriate.  The 
extended database given in the compact disc issued by the ICRP gives inhalation DCFs for ten 
aerosol sizes (0.001 µm to 10 µm AMAD) using the ICRP 68/72 models.7 
Typical SRS Application 
Most radiological inventories at SRS exist in oxide powder, oxide metal or nitrate solution 
forms.  For inventories that are well characterized, the approach summarized above generally 
applies.  Even for well-characterized inventories, however, potential environmental effects 
associated with the some accident scenarios (e.g., fire, explosion, criticality) may introduce 
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uncertainty in the chemical form of the released material.  Also, liquid solutions in some SRS 
facilities may change chemical form during processing so the consequence analysis needs to 
cover both material forms.  A common situation in consequence analyses performed at SRS is to 
consider the possibility of both nitrate and oxide chemical compound forms in order to address 
the uncertainties in chemical form of the released material during postulated accidents. 
For each radionuclide, a reasonably conservative DCF is selected for use based on considering 
the various lung absorption types that are represented by the nitrate and oxide chemical 
compound forms and selecting the maximum DCF from among the lung absorption types 
representing these forms.  In order to implement this approach, five distinct cases must be 
addressed.  These five cases and the particular strategy for handling each case are summarized in 
Table 1. 
Table 1. Strategy for Source Terms that May be Either Nitrate or Oxide Chemical Forms. 
Case Case Description Strategy 
1 All chemical compounds of the radionuclide are 
assigned to a single lung absorption type. 
The inhalation DCF is based on the single lung 
absorption type that is identified for all chemical 
compounds. 
2 The oxide form and nitrate form are explicitly 
assigned to the same lung absorption type. 
The inhalation DCF is based on the lung absorption 
type that is identified for the nitrate and oxide forms. 
3 The oxide form is explicitly assigned to one lung 
absorption type and the nitrate form is explicitly 
assigned to a different lung absorption type. 
The inhalation DCF is specified on the basis of the 
higher of the two inhalation DCFs considering the 
lung absorption type for the oxide and nitrate forms. 
4 Either the oxide form or the nitrate form but not 
both are explicitly assigned to a lung absorption 
type and a different lung absorption type covers 
“unspecified compounds.” 
The inhalation DCF is specified on the basis of the 
higher of the two inhalation DCFs considering the 
lung absorption type for the oxide or nitrate forms 
and the lung absorption type for “unspecified 
compounds.”  
5 Neither the oxide form nor the nitrate form is 
explicitly assigned to a lung absorption type and 
more than one lung absorption type option is 
provided. 
In absence of other information, the inhalation DCF 
is specified on the basis of the highest inhalation 
DCF among those associated with a listed lung 
absorption type in Annexe F of ICRP Publication 68. 
Ill Characterized Inventory 
When little information is available on the chemical form of the inventory, a bounding set of 
default inhalation DCFs is appropriate.  The method for specifying the inhalation DCF for each 
radionuclide is the same as the strategy listed for Case 5 in Table 1.  Specifically, the inhalation 
DCF is specified on the basis of the highest inhalation DCF among those associated with a listed 
lung absorption type in Annexe F of ICRP Publication 68 for the given radionuclide. 
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Plutonium 
Since plutonium in the source term is often the main contributor to dose, specifying the 
appropriate inhalation DCFs for plutonium radionuclides is especially important and thus given 
particular emphasis.  In previous ICRP guidance, all plutonium oxide forms were assigned to the 
same solubility category (least soluble category).8  Annexe F of ICRP Publication 68 makes a 
subtle, but important, distinction in the assignment of plutonium oxide material to a lung 
absorption type.  Recent guidance from ICRP publications on plutonium lung absorption has 
focused on the various oxide forms of plutonium and the importance of the material’s history, 
especially the method of oxide formation.  High-fired plutonium oxide results in insoluble 
material form with a slower lung absorption rate than plutonium oxide that results from air 
oxidation at ambient temperatures.8  Thus, only insoluble oxide is assigned to lung absorption 
type S, and all other plutonium compounds are assigned to lung absorption type M.3  Incomplete 
oxidation seems to be the contributing factor for the plutonium oxide that forms at ambient 
temperatures being more soluble and having absorption characteristics representative of lung 
absorption type M.8  Complete oxidation occurs at high temperatures (~ 1000 °C and above for 
studies cited in ICRP 71) and results in lung absorption S8 with a lower inhalation DCF3,4. 
When specific knowledge of the origin of the plutonium oxide in the source term is lacking, or it 
is not clear how environmental effects (e.g., fire, explosion, criticality) from the assumed 
accident condition will affect the material-at-risk, the analyst should conservatively assume the 
soluble oxide form and use the higher inhalation DCFs that are associated with lung absorption 
type M. 
Concluding Remarks 
The methodology at the SRS for specifying inhalation DCFs is summarized in this paper.  
Uncertainties in chemical form that result from either processing uncertainties or accident-related 
transformations are considered.  For each radionuclide, a reasonably conservative DCF is 
selected for use based on considering the various lung absorption types that are represented by 
possible chemical compound forms and selecting the maximum DCF from among the lung 
absorption types representing these forms.  Following recent ICRP guidance, the assignment of 
plutonium oxide material to a lung absorption type considers material’s history as it relates to the 
method of oxide formation. 
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